Our study group formed by the collaboration of clinical research groups and international collaborators including pharma experts in the interest of sharing new data in a unique platform through conferences and meetings with the aim of studying MASLD and related pathologies Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD) is currently the most common liver disorder both in the US and Europe. The fatty liver may progress to non-alcoholic steatohepatitis (NASH, now MASH), which markedly increases the risk of cirrhosis and hepatocellular carcinoma. MASLD is the hepatic manifestation of the metabolic syndrome and characterizes the majority of patients with type 2 diabetes.
1. To advance our understanding of the prevalence, diagnosis, pathogenesis, prevention and treatment of MASLD.
2. To enable hepatologists and diabetologists and other specialists in cognate disciplines to interact.
